SU6668 in idiopathic myelofibrosis - A rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis

Medical Hypotheses

Volumn 61, Issue 2, 2003, Pages 244-247

  Hasselbalch, Hans Carl ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; GROWTH FACTOR RECEPTOR; GROWTH PROMOTOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; BONE MARROW; CELL PROLIFERATION; CLINICAL TRIAL; CONNECTIVE TISSUE; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DYSPLASIA; ENZYME INHIBITION; FIBROGENESIS; HUMAN; IDIOPATHIC DISEASE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 0042623466     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00155-5     Document Type: Article

References (30)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342(17): 1255-1265.
2. Thiele J., Kvasnicka H. M., Fischer R., Diehl V. Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update. Leuk Lymphoma 1997; 24: 463-481.
3. Hasselbalch H. C. Idiopathic myelofibrosis. Am J Hematol 1990; 34: 291-300.
4. Cervantes F., Pereira A., Esteve J., Rafel M., Cobo F., Rozman C., Montserrat E. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97: 635-640.
5. Thiele J., Zankovich R., Steinberg T., Kremer B., Fischer R., Diehl V. Primary (essential) thrombocyhemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis. A critical evaluation of clinical and histomorphological data. Acta Haematol 1989; 81: 192-202.
6. Castro-Malaspina H. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. In: Myelofibrosis and the Biology of Connective Tissue. 1984: 427-454.
7. Le Bousse-Kerdiles M. C., Martyre M. C. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999; 78: 437-444.
8. Siitonen T., Savolainen E. R., Koistinen P. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes. Leukemia 1994; 8(4): 631-637.
9. Kimura A., Nakata Y., Katoh O., Hyodo H. c-kit point mutation in patients with myeloproliferative disorders. Leuk Lymphoma 1997; 25(3-4): 281-287.
10. Martyre M. C., Magdelenat H., Bryckaert H., Laine-Bidron C., Calvo F. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-b in patients with myelofibrosis with myeloid, metaplasia. Br J Haematol 1991; 77: 80-86.
11. Martyre M. C., Le Bousse-Kerdiles M. C., Romquin N., Chevillard S., Praloran V., Demory J. L., Dupriez B. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997; 97: 441-448.
12. + hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996; 88(12): 4534-4546.
13. Roberts A. B., Sporn M. B. The transforming growth factor β. In: M. B. Sporn, A. B. Roberts (eds). Peptide Growth Factors and their Receptors, Handbook of Experimental Pharmacology. Heidelberg, Germany: Springer, 1990: 419.
14. Gospodarowicz D., Ferrara N., Schweigerer L., Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocrine Rev 1987; 8: 95.
15. Cashman J. D., Eaves A. C., Raines E. W., Ross R., Eaves C. J. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β. Blood 1990; 75: 96.
16. Gabrilove J. L., Wong G., Bollenbacher E., White K., Kojima S., Wilson E. L. Basic fibroblast growth factor counteracts the suppressive effect of transforming growth factor β on human myeloid progenitor cells. Blood 1993; 81: 909.
17. Barosi G., Viarengo G., Rosti V., Piaggio G., Marchetti M., Frassoni F. Diagnostic and clinical relevance of the number of circulating CD34 positive cells in myelofibrosis with myeloid metaplasia. Blood 2001; 98(12): 3249-3255.
18. Gilbert H. S., Praloran V., Stanley E. R. Increased CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension. Blood 1989; 74: 1231.
19. Hasselbalch H. C. Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism. Dan Med Bull 1993; 40: 39.
20. Raimundo F. D., Azzaro M. P., Palumbo G. A., Bagnoto S., Stagno F., Giustolisi G. M., Cacciola E., Sortino G., Guglielmo P., Giustolisi R. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 2001; 15: 976-980.
21. Burkhardt R., Bartl, Beil E., Demmler K., Hoffman E., Kronseder A. Myelofibrosis-Osteomyelosclerosis Syndrome - Review of Literature and Histomorphology. In: Advances in the Biosciences, Dahlem Workshop on Myelofibrosis-Osteomyelosclerosis Syndrome. Berlin Nov 13-15, 16. 1974: 9-56.
22. Lisse I., Hasselbalch H., Junker P. Bone marrow stroma in idiopathic myelofibrosis and related diseases. An immunohistochemical study. APMIS 1991; 99: 1171-1178.
23. Boecklin F., Hasserjian R. P., Olavarria E., Armstrong L., Mulvanny M., Eades A., Chase A., Bua M., Zaiac M., Apperley J., Goldman J. M. Anti-fibrogenic effect of the tyrosine kinase inhibitor STI-571 on bone marrow fibrosis in chronic myeloid leukemia. Blood 2000; 94: 734a.
24. + cells identifies a group of patients with myelofibrosis with myeloid metaplasia (MMM) who efficiently responds to STI571. Blood Suppl. ASH 2001 abstract 2630.
25. Tefferi A., Mesa R. A., Gray L. A., Steensma D. P., Camoriano J. K., Elliott M. A., Pardanani A., Ansell S. M., Call T. G., Colon-Otero G., Geyer S. M., Hanson C. A., Dewald G. W., Kaufmann S. H. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 2002; 99: 3854-3856.
26. Fong T. A., Shawver L. K., Sun L. et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
27. Laird A. D., Vajkoczy P., Shawver L. K. et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60: 4152-4160.
28. Smolich B. D., Yuen H. A., West K. A., Giles F. J., Albitar M., Cherrington J. M. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid keukemia cell line and in acute myeloid keukemia blasts. Blood 2001; 97: 1413-1421.
29. Fiedler W., Graeven U., Ergun S. et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870-1875.
30. Duhrsen U., Martinez T., Vohwmkel G., Ergun S., Sun L., McMahon J., Durig J., Hossfeld D. K., Fiedler W. Effects of vascular endothelial and platelet-derived growth factor receptors on long-term cultures from normal human bone marrow. Growth Factors 2001; 19(1): 1-17.